Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 12/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | EIF4E | P06730 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23294821 | 0.91 | HRH3 (0.41) | HRH4SUV39H2PIK3CAKDREIF4E | |
| SCHEMBL23294790 | 0.91 | CYP1A2 (0.37) | HRH4SUV39H2PIK3CAEIF4EKCNH2 | |
| SCHEMBL23294882 | 0.89 | CTSS (0.40) | PIK3CAEIF4EKCNH2MKNK1MKNK2 | |
| SCHEMBL23294859 | 0.87 | PARP1 (0.43) | HRH4KDREIF4EKCNH2MKNK1 | |
| SCHEMBL23294803 | 0.86 | ATM (0.41) | PIK3CA | |
| SCHEMBL23294819 | 0.86 | PDE10A (0.35) | HRH4SUV39H2KDRPDE10A | |
| SCHEMBL23294875 | 0.85 | MAOB (0.38) | SUV39H2PIK3CAMAOBHTR6EIF4E | |
| SCHEMBL23294894 | 0.79 | CTSS (0.43) | HRH4 | |
| SCHEMBL23294791 | 0.79 | MAOB (0.34) | SUV39H2PIK3CAMAOBHTR6EIF4E | |
| SCHEMBL23294788 | 0.78 | PIK3CD (0.37) | PIK3CAMAOBHTR6EIF4EKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2023-01-10 | — | — | US | claimed |
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | claimed |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2023-01-10 | — | — | US | disclosed |
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | CHEK2, CHEK1, ATM | HRH4 2164/4885SUV39H2 2655/4885PIK3CA 93/4885 |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | CHEK2, CHEK1, ATM | HRH4 2164/4885SUV39H2 2655/4885PIK3CA 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.